190 related articles for article (PubMed ID: 38155717)
1. The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R; Kamireddy AP; Hussaini SM; Chatterjee S; Hasan Q; Jain J
Front Genet; 2023; 14():1256756. PubMed ID: 38155717
[TBL] [Abstract][Full Text] [Related]
2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
3. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
4. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
5. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
[TBL] [Abstract][Full Text] [Related]
6. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.
Li D; Ding L; Ran W; Huang Y; Li G; Wang C; Xiao Y; Wang X; Lin D; Xing X
Thorac Cancer; 2020 Sep; 11(9):2580-2589. PubMed ID: 32729257
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
9. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
10. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
11. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
12. Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
Liu X; Jiang G; Sun X; Su G; Zhang X; Shen D; Yan N
Front Oncol; 2023; 13():1275575. PubMed ID: 38023198
[TBL] [Abstract][Full Text] [Related]
13. Genomic Landscape of NSCLC in the Republic of Ireland.
Keogh RJ; Barr MP; Keogh A; McMahon D; O'Brien C; Finn SP; Naidoo J
JTO Clin Res Rep; 2024 Feb; 5(2):100627. PubMed ID: 38333230
[TBL] [Abstract][Full Text] [Related]
14. Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival.
Martínez-Herrera JF; Sánchez Domínguez G; Juárez-Vignon Whaley JJ; Carrasco-Cara Chards S; López Vrátný C; Guzmán Casta J; Riera Sala RF; Alatorre-Alexander JA; Seidman Sorsby A; Cruz Zermeño M; Conde Flores E; Flores-Mariñelarena RR; Sánchez-Ríos CP; Martínez-Barrera LM; Gerson-Cwilich R; Santillán-Doherty P; Jiménez López JC; López Hernández W; Rodríguez-Cid JR
J Thorac Dis; 2024 Jan; 16(1):161-174. PubMed ID: 38410597
[TBL] [Abstract][Full Text] [Related]
15. The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
Cai L; Chen Y; Tong X; Wu X; Bao H; Shao Y; Luo Z; Wang X; Cao Y
Int J Cancer; 2021 Apr; ():. PubMed ID: 33811322
[TBL] [Abstract][Full Text] [Related]
16. Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program.
Jalal SI; Guo A; Ahmed S; Kelley MJ
Semin Oncol; 2022 Jul; ():. PubMed ID: 35902275
[TBL] [Abstract][Full Text] [Related]
17. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
18. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.
Passaro A; Attili I; Rappa A; Vacirca D; Ranghiero A; Fumagalli C; Guarize J; Spaggiari L; de Marinis F; Barberis M; Guerini-Rocco E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946519
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
20. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S; Fung AS; Perdrizet KA; Chen K; Li JJN; Le LW; Cabanero M; Karsaneh OAA; Tsao MS; Morganstein J; Ranich L; Smith AC; Wei C; Cheung C; Shepherd FA; Liu G; Bradbury P; Pal P; Schwock J; Sacher AG; Law JH; Stockley TL; Leighl NB
Curr Oncol; 2022 Jun; 29(7):4428-4437. PubMed ID: 35877212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]